PEPTAMR Biomimetic antimicrobial peptide inspired by insects to combat multi-drug-resistant Acinetobacter baumannii
- Coordinator
- Omnix Medical Ltd, Israel
- Runs
- 1 June 2026 to 31 May 2029
- Status
- Running
- EU funding
- €7.9m
- Total cost
- €7.9m
- Partners
- 5 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101287207
What the project is doing
In the project's own words, from its summary on CORDIS.
OMN6 is a synthetic cyclic peptide developed to treat infections caused by multidrug resistant A. baumannii, a WHO critical priority pathogen linked to high mortality. After a clean Phase 1 and an ongoing Phase 2, PEPTAMR moves OMN6 toward late clinical development with the goal of delivering a regulatory-ready Phase 3 packageThe project will expand clinical data collection across Europe, complete the preclinical work needed to justify dosing and indications, run a healthy-volunteer lung penetration study, and finalise a stable, scalable clinical formulation ready for manufacturing.
A companion diagnostic roadmap will be prepared to help clinicians identify patients who can benefit most. Led by OMN with VIV, MUV, NKUA and ECR, PEPTAMR combines industry and academic strengths to produce the assays, models and clinical evidence that will enable licensing and broad hospital use. The ultimate aim is to provide hospitals with a safe, effective, and practical therapy for a deadly, hard to treat pathogen.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Omnix Medical Ltd | Jerusalem | Israel | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Ethniko Kai Kapodistriako Panepistimio Athinon | Athina | Greece | Participant |
| Vivexia | Dijon | France | Participant |
| Stichting European Clinical Research Alliance on Infectious Diseases | Utrecht | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI